C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 145 affiliates and more than 42,000 employees. The company's key assets of interest are: respiratory disease, cardiovascular disease, Parkinson's disease, HIV, thromboembolic disease and cerebrovascular disease. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

The business areas consist of Human Pharmaceuticals and Animal Health. In 2010, 42,224 employees were in 145 affiliated companies worldwide, research and development (R&D) facilities were in seven sites and 20 production plants in 13 countries. Boehringer Ingelheim's Pharma Chemicals business has pioneered the commercial production of monomers and biodegradable polymers for more than 20 years.